PIK3CA and ovarian carcinoma: It is also possible that PI3K/mTOR pathway inhibition could prolong progression-free survival by supporting dormancy; however, prolonged maintenance therapy using such targeted agents could yield the emergence of additional mechanisms of resistant disease beyond that of platinum resistance already prevalent in ovarian cancer [55].